TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
Summary
Company delivers 42% revenue growth year-over-year and strengthens balance sheet with gross proceeds from recent private placementExpands commercial footprint, and invests further in new applications for TriNav already in useUpdates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDDCompany to Host Conference Call and Webcast today at--(BUSINESS WIRE)--May 15, 2025-- (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended , and provides an operational update and revised financial guidance.Our strong first quarter performance reflects the growing impact of our PEDD platform across a variety of solid tumor indications, said , President and CEO of TriSalus. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Companys investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.Statements made in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.